Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
All I can observe is that AVXL is not dancing.
Lets hope AVXL belongs in the creativity box ‘cause at the moment we are in the not-loved box
Fact: AVXL announced that BIIB would test 2-73 for MS and then BIIB goes partnering with another company.
I am awaiting the predictable defense:
1) BIIB is still testing, 15 months on
2) BIIB offered peanuts for 2-73
3) Missling is a “good doctor” and has retails best interest at heart, just trust him
BIIB prefers ALKS to AVXL for MS
They had a look at 2-73 and thats it.
You are right, two years to design a p2/3 trial definitely qualifies as “taking your time”
Thanks for highlighting that two years came and went since that PR. And still no larger trial.
They two years of safety. Thats about it.
The efficacy still needs to be proven in a larger trial.
We are dependent on the FDA new rules. Why was that never attached to all the statements that three trials would be starting this year? Too much anticipation created without control on timing.
Science is not for conference calls.
Wait, I thought the DOD had withdrawn their 13 mil grant. I am sure that was claimed on this board.
Luckily the DOD has faith in our science.
That’s called “doing due dilligence” and searching Google.
Oh crap, more bad news!!
;)
Just remember that 3 phase 2 trials are up and running.
It’s not about the delay, it’s about not meeting self-imposed deadlines that were stated and confirmed multiple times. It’s about the management of a company and shareholder communication.
And most importantly: three phase 2-trials are recruiting.
Science needs to run its course and results will do the rest.
How about just getting the trial up and running ???
So Missling has to wait until the new rules are implemented. He has no control on the timing of this and yet has confirmed multiple times that the tree trials will start in 2017.
The “Good Doctor” only sets Anavex up for self-inflicted wounds for failing to meet self-imposed timelines. Not smart!
We can only hope that the FDA will deliver on time. When was the last time that happened?
In the June17 presentation he was still mentioning a potential data read-out end of this year. At this stage a trial initiation will be regarded as good news.
Manage expectations!
When you think that the companies milestones earlier in the year were mentioning potential data read-out end 2017, then it really is getting pathetic.
So much doom and gloom predicted to happen with TapImmune by Nostradamus and yet the earth still spins and the prophecy is fake.
Standard practice to sell part of awarded shares to cover the tax cost.
Facts matter.
It must be hard to watch the ONCS shareprice go up.
This is why the new CEO sold shares: for tax reasons.
Facts matter more than innuendo.
“Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the restricted stock award.”
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12292950&RcvdDate=9/25/2017&CoName=TAPIMMUNE%20INC.&FormType=4&View=html
Can only qualify this as unsubstantiated rumour without a connection to reality.
What happened today?
No need to repost the same thing over and over, this board has a search function.
Thanks for highlighting. But going off what we read on here and the multiple confirmations that three trials will start in 2017...
I was always told to shutup about timing if you do not control it.
If that is the case then he is totally dependent on how fast or slow the FDA moves. Totally possible 2017 is not feasible and nothing he can do about it.
Time will tell, if only Missling could get the damn trial up and running!
The problem with 6 patients is that they are not representative for a population and therefore the results cannot be extrapolated. To much probabilty of patient anomaly. Hence why the FDA requires bigger phase 3 trials.
Get the damn thing started Missling!
Time will tell when at last a decent sized trial will start.
But they seem to put all egs into those 5 super responders. Achilles heel.
Its a wishfull thinking effect
Like in Nov15 or July16?
Yeah lets talk Nobel prizes.
That really doesn't put the cart in front of the horse.
How about actually starting a decent sized trial ???
60 days left to start three trials...
Thanks for bringing a realistic perspective to the discussion.
Why wait for $2 if you can wait for $1?
Favourite quote from “the Kings Speech”:
“Waiting for a King to apologise, one can wait rather a long wait”
Yes the good doctor is really good ;)
Oh good, then we don’t waist scarce resources on family trips.